Dr. Vargas received his MD from Universidad San Martin de Porres in Lima, Peru. He completed a residency in Internal Medicine at Albert Einstein Medical Center, followed by a fellowship in Hematology/Oncology at Jackson Memorial Hospital/University of Miami Miller School of Medicine. Dr. Vargas joins us from Pfizer, where he served as the Medical Director.
Dr. Vargas’s primary clinical interest is in the treatment of patients with hematologic malignancies, including leukemia, lymphoma and multiple myeloma. His research focuses on improving the outcomes of patients with acute myeloid and lymphoid leukemias through innovative clinical trials. He is also interested in cellular therapies and their applications in the treatment of patients with hematologic malignancies.
CLINICAL TRIAL 20733
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzomab Ozogamicin (a conjugated anti-CD22 monoclonal antibody) to Frontline Therapy in Young Adults (ages 18-39 years) with Newly Diagnosed Precusor B-cell ALL
Condition: Malignant Hematology
Open (affiliates only)
Vargas-Madueno F, Gould E, Valor R, Ngo N, Zhang L, Villalona-Calero MA. EML4-ALK Rearrangement and Its Therapeutic Implications in Inflammatory Myofibroblastic Tumors. Oncologist. 2018 Oct.23(10):1127-1132. Pubmedid: 29739898. Pmcid: PMC6263129.
Park W, Kwon D, Saravia D, Desai A, Vargas F, El Dinali M, Warsch J, Elias R, Chae YK, Kim DW, Warsch S, Ishkanian A, Ikpeazu C, Mudad R, Lopes G, Jahanzeb M. Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab. Clin Lung Cancer. 2018 May.19(3):280-288.e4. Pubmedid: 29336998.
Swords RT, Azzam D, Al-Ali H, Lohse I, Volmar CH, Watts JM, Perez A, Rodriguez A, Vargas F, Elias R, Vega F, Zelent A, Brothers SP, Abbasi T, Trent J, Rangwala S, Deutsch Y, Conneally E, Drusbosky L, Cogle CR, Wahlestedt C. Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study. Leuk Res. 2018 Jan.64:34-41. Pubmedid: 29175379. Pmcid: PMC5756519.
Swords R, Sznol J, Elias R, Watts J, Zelent A, Martin E, Vargas F, Bethel-Ellison S, Kobetz E. Acute leukemia in adult Hispanic Americans: a large-population study. Blood Cancer J. 2016 Oct.6(10):e484. Pubmedid: 27740629. Pmcid: PMC5098265.
Campuzano-Zuluaga G, Deutsch Y, Salzberg M, Gomez A, Vargas F, Elias R, Kwon D, Goodman M, Ikpatt OF, Chapman JR, Watts J, Vega F, Swords R. Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better?. Am J Hematol. 2016 Mar.91(3):277-282. Pubmedid: 26663264.
Davila CD, Vargas F, Huang KH, Monaco T, Dimou A, Rangaswami J, Figueredo VM. Dipstick proteinuria is an independent predictor of high on treatment platelet reactivity in patients on clopidogrel, but not aspirin, admitted for major adverse cardiovascular events. Platelets. 2015 Dec.26(7):651-656. Pubmedid: 25354134.
Junpaparp P, Buppajarntham S, Madueno FV, Varadi G. Concomitant typhlitis and Clostridium difficile colitis developed after first R-CHOP chemotherapy in a non-Hodgkin lymphoma patient. BMJ Case Rep. 2013 Apr.2013. Pubmedid: 23598937. Pmcid: PMC3645077.
The Provider Rating is an average of all responses to specific care provider-related
questions from our nationally-recognized
Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive
different surveys, and the volume of responses will vary by question.
Comments are gathered from specific care provider-related questions from our
Patient Satisfaction Survey . The comments are submitted by patients
and reflect their views and opinions. Patients are de-identified for confidentiality and
We post both positive and negative comments from the surveys. We do not post comments
that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may
risk the privacy of our patients.
A “[…]” in the comments below indicates de-identified patient information or comments that
are unrelated to the patient’s experience with the visit to the provider, such as
comments related to another provider, about the survey itself, or otherwise completely
Not all providers will have a star rating or comments. In order to ensure accuracy of our
ratings, we only display ratings for providers who have a minimum of 30 completed from
the previous 12 months.
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey
Patient Satisfaction Survey. If a provider does not have ratings or comments listed it
can be for several reasons, including:
The provider has not yet received the minimum number of patient satisfaction surveys
to be eligible for display. We require a minimum of 30 surveys before we post
results to ensure that the rating is statistically reliable and a true reflection of
He or she may be a researcher or other type of provider that does not see patients.
The provider practices in a specialty or office that does not use the specified
surveys currently used for these ratings.
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate buttonbelow. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub